Maximum tolerated dose of a new drug is evaluated in
**Core Concept**
The maximum tolerated dose (MTD) of a new drug is a critical pharmacological parameter that determines the optimal dose required to achieve therapeutic efficacy while minimizing toxicity. It is a key concept in pharmacology and clinical trials, reflecting the dose at which the benefits of the drug outweigh its adverse effects.
**Why the Correct Answer is Right**
The MTD is typically evaluated in a Phase I clinical trial, where a small group of healthy volunteers or patients with a specific condition receive escalating doses of the new drug. The MTD is the dose at which the majority of participants experience adverse effects, but these effects are still manageable and do not lead to serious harm. This dose is determined through a process called dose escalation, where the dose is increased incrementally until the desired level of toxicity is reached. The MTD is an important milestone in the development of new drugs, as it informs subsequent clinical trials and helps to establish a safe and effective dosing regimen.
**Why Each Wrong Option is Incorrect**
**Option A:** This is incorrect because the MTD is not typically evaluated in a Phase II clinical trial, which focuses on assessing the efficacy and safety of a drug in a larger group of patients with a specific condition.
**Option B:** This is incorrect because the MTD is not the same as the therapeutic index (TI), which is a measure of a drug's safety margin between the therapeutic dose and the dose that causes toxicity.
**Option C:** This is incorrect because the MTD is not evaluated in a Phase III clinical trial, which is a large-scale trial that aims to confirm the efficacy and safety of a drug in a diverse population.
**Clinical Pearl / High-Yield Fact**
The MTD is often estimated using mathematical models, such as the Fibonacci sequence, to optimize dose escalation and minimize the risk of adverse effects. This approach allows researchers to identify the optimal dose range for further clinical development.
**Correct Answer:** D. Phase I clinical trial.